5 MORE COVID-19 VACCINES UNDER TRIALS IN INDIA 2021
In order to respond quickly and effectively to the COVID-19 pandemic, a broad range of candidate COVID-19 vaccines are being investigated globally using various technologies and platforms. These include viral-vectored, protein subunit, nucleic acid (DNA, RNA), live attenuated and inactivated vaccines. Previously two candidates of the vaccine have been approved for emergency use i.e. Covishield & Covaxin. Some of these candidates have entered under clinical trials.
- ZyCov-D
- Biological E’s novel Covid-19 vaccine
- BBV154 – Intranasal vaccine
- COVOVAX
- mRNA based vaccine (HGCO19)
ZyCoV-D
Zydus Cadila, focused on discovering and developing NCEs, Novel Biologicals, Biosimilars and Vaccines, announced that its plasmid DNA vaccine to prevent COVID-19, ZyCoV-D. Safety in Phase I clinical trial of ZyCoV-D in healthy subjects established as endorsed by the independent Data Safety Monitoring Board (DSMB). Zydus commenced Phase II trial.
- DCGI approval for Phase I & Phase II Human Clinical Trials RECEIVED
- Phase I Human Clinical Trial COMPLETED
- Phase II Human Clinical Trial COMPLETED
- Phase III Human Clinical Trial ONGOING
- DCGI approval for Phase III Human Clinical
Biological E’s novel Covid-19 vaccine
Biological E. Limited is conducting a prospective open label randomised Phase-I seamlessly followed by Phase-II study to assess the safety, reactogenicity and immunogenicity of Biological E’s novel Covid-19 vaccine containing Receptor Binding Domain of SARS-CoV-2 for protection against Covid-19 disease when administered intramuscularly in a two dose schedule(0, 28D) to healthy volunteers.
- DCGI approval for Phase I & Phase II Human Clinical Trials RECEIVED
- Phase I/II Human Clinical Trial ONGOING
BBV154 – Intranasal vaccine
Bharat Biotech is conducting Multicenter Study to Evaluate the Reactogenicity, Safety, and Immunogenicity of an Intranasal Adenoviral vector COVID-19 vaccine (BBV154) in Healthy Volunteers. BBV154 is an intranasal vaccine that stimulates a broad immune response – neutralizing IgG, mucosal IgA, and T cell responses. Immune responses at the site of infection (in the nasal mucosa) – essential for blocking both infection and transmission of COVID-19.
- DCGI approval for Phase I Human Clinical Trials RECEIVED
- Phase I Human Clinical Trial ONGOING.
COVOVAX
Indian Council of Medical Research and Serum Institute of India jointly performing a phase 2/3, observer-blind, randomized, controlled study to determine the safety and immunogenicity of COVOVAX [SARS-CoV-2 recombinant spike protein nanoparticle vaccine (SARS-CoV-2 rS) with Matrix-M1™ adjuvant] in Indian adults.
- DCGI approval for Phase 2/3 Human Clinical Trial RECEIVED
- Phase 2/3 Human Clinical Trial ONGOING
mRNA based vaccine (HGCO19)
Randomized, Phase I/II, Placebo-controlled, Dose-Ranging, study to evaluate the Safety, Tolerability and Immunogenicity of the candidate HGCO19 (COVID-19 vaccine) in healthy adult subjects. The trial is being conducted by Gennova Biopharmaceuticals Limited.
- DCGI approval for Phase I/II Human Clinical Trial RECEIVED
- Phase I/II Human Clinical Trial ONGOING.
Bibliography: Indian Council of Medical Research (ICMR) & WHO.
